EXACT Sciences Corp (NASDAQ:EXAS)
CAPS Rating:
An applied genomics company that develops proprietary DNA-based technologies for use in the detection of cancer.
Growing the love for investing
An applied genomics company that develops proprietary DNA-based technologies for use in the detection of cancer.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Exact Sciences stakes its future on a pioneering and extremely promising gambit - replacing the colonoscopy with a highly-reliable, completely non-invasive test for rectal and intestinal cancer. Its test allows for an inexpensive procedure which would mean either [1] clean bill of health without the colonoscopy ordeal or [2] a fairly specific diagnosis that would insure the need for scoptic and surgical follow-on. The tests could be done much more frequently as well. Cramer, Feuerstien, and a number of others like this stock, at least as a speculation, and it's rated a "strong buy" by others. Marketing could impede its profitability but then it also represents a natural take-over for a big pharma suffering the dyspepsia of patent expiration. I bought some.